Traduction de «led by particularly strong » (Néerlandais → Français) :

The six top emerging markets (USD 710 million, +7% cc) were led by particularly strong growth in India (+26% cc) and Russia (+20% cc).
Les six principaux marchés émergents (USD 710 millions, +7% tcc) ont été emmenés par une croissance particulièrement forte en Inde (+26% tcc) et en Russie (+20% tcc).

Animal Health growth was mainly led by the strong performance of Interceptor and Sentinel in the US and Milbemax in Europe.
La croissance d’Animal Health a été emmenée principalement par la forte performance d’Interceptor et de Sentinel aux Etats-Unis et de Milbemax en Europe.

At the same time, all divisions are seeking to expand in emerging markets where growth in the second quarter was 16%, with particularly strong performances in South Korea (23%) and Russia (41%).
En même temps, toutes les divisions cherchent à s’étendre dans les marchés émergents où nous avons enregistré, au deuxième trimestre, une croissance de 16%, avec des performances particulièrement fortes en Corée du Sud (23%) et en Russie (41%).

Consumer Health: USD 1.6 billion (+20%, +13% lc) Very strong growth across all businesses was led by OTC expansion at a double-digit rate in local currencies on the strength of the US launch of Prevacid24HR in November and strong demand for “cough & cold” products.
Consumer Health: USD 1,6 milliard (+20%, +13% en m. l).

Basel, October 22, 2009 — Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis, said: “I am pleased with our strong underlying performance, led by the momentum of our Pharmaceuticals business, outpacing the competition and benefiting from innovative product growth rejuvenating the portfolio.
Bâle, le 22 octobre 2009 – En commentant les résultats, le D r Daniel Vasella, Président et Administrateur délégué de Novartis a déclaré: «Je suis heureux de l’excellente performance sous-jacente, emmenée par l’essor des activités de Pharmaceuticals. Cette division surpasse la concurrence et bénéfice de la croissance des produits innovateurs qui rajeunissent le portefeuille.

The strong underlying business expansion, with net sales rising 11% lc, and productivity savings led to operating income gains and enabled significant investments in new product launches, key development projects and geographic expansion.
La forte expansion sous-jacente, qui s’est traduite par une hausse de 11% du chiffre d’affaires net en monnaies locales, et des gains de productivité ont conduit à une amélioration du résultat opérationnel. Celle-ci a permis de procéder à des investissements importants dans les lancements de nouveaux produits, dans des projets-clés de développement et dans une extension géographique.

The continued strong growth in biosimilars was led by products such as Omnitrope, which has made steady gains against originator growth hormone deficiency treatments, as well as the launches of oncology indications of Binocrit (epoetin alfa) and Zarzio (filgrastim), setting the stage for further expansion of Sandoz’s position as the biosimilars market leader.
La forte progression continue des biosimilaires a été menée par des produits comme Omnitrope, qui na cessé de gagner du terrain face aux traitements originaux du déficit de l’hormone de croissance ainsi que par les lancements des indications oncologiques de Binocrit (époétine alfa) et Zarzio (filgrastim). Ainsi la voie est ouverte pour permettre à Sandoz de conforter sa position de leader du marché des biosimilaires.

These roadshows were evaluated by the attendees and received a particularly high score; the roadshows also received a lot of coverage in the trade press and have led to a list of questions and answers (FAQ) which is discussed and added to at each presentation.
These roadshows were evaluated by the attendees and received a particularly high score; the roadshows also received a lot of coverage in the trade press and have led to a list of questions and answers (FAQ) which is discussed and added to at each presentation.

Mondillo et al 42 2002 RCT yes 188 Among subjects undergoing major vascular surgery, severity and extent of ischemia during DSE and presence of > 3 reversible perfusion defects are strong predictors of cardiac events particularly in moderate risk patients
Mondillo et al 44 2002 RCT yes 188 Among subjects undergoing major vascular surgery, severity and extent of ischemia during DSE and presence of > 3 reversible perfusion defects are strong predictors of cardiac events particularly in moderate risk patients